ArticleJournal of pharmaceutical sciences2010
Swellable microparticles as carriers for sustained pulmonary drug delivery.
Article in Journal of pharmaceutical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Gelatin-Based Microspheres for Sustained Ketoprofen Delivery in Difficult-to-Heal Wounds.Polymers · 2026Article
- Hydrogel Microspheres as Versatile Platforms for Biomedical Research: Design, Properties, and Applications.MedComm · 2025Review
- Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets.Annual review of biomedical engineering · 2024Review
- Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery.Scientific reports · 2024Article
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
- An evolving perspective on novel modified release drug delivery systems for inhalational therapy.Expert opinion on drug delivery · 2023Review
- Nebulization of Model Hydrogel Nanoparticles to Macrophages at the Air-Liquid Interface.Frontiers in chemical engineering · 2023Article
- Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics · 2022Review
- Hyaluronic Acid Hydrogels for Controlled Pulmonary Drug Delivery-A Particle Engineering Approach.Pharmaceutics · 2021Article
- Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.Acta pharmaceutica Sinica. B · 2021Review
- Hydrogel microparticles for biomedical applications.Nature reviews. Materials · 2020Article
- PEGylated Chitosan for Nonviral Aerosol and Mucosal Delivery of the CRISPR/Cas9 System in Vitro.Molecular pharmaceutics · 2018Article
- Influence of polymeric carrier on the disposition and retention of 20(R)-ginsenoside-rg3-loaded swellable microparticles in the lung.Drug delivery and translational research · 2018Article
- Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.Acta pharmacologica Sinica · 2017Review
- Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.Pharmaceutical research · 2015Article
- Inhaled nano- and microparticles for drug delivery.Global cardiology science & practice · 2015Review
- High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.AAPS PharmSciTech · 2014Article
- Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery.AAPS PharmSciTech · 2014Article
- Polymeric nanoparticles for pulmonary protein and DNA delivery.Acta biomaterialia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In this investigation, novel biodegradable physically crosslinked hydrogel microparticles were developed and evaluated in vitro as potential carriers for sustained pulmonary drug delivery. To facilitate sustained release in the lungs, aerosols must first navigate past efficient aerodynamic filtering to penetrate to the deep lung (requires small particle size) where they must then avoid rapid macrophage clearance (enhanced by large particle size). The strategy suggested in this study to solve this problem is to deliver drug-loaded hydrogel microparticles with aerodynamic characteristics allowing them to be respirable when dry but attain large swollen sizes once deposited on moist lung surfaces to reduce macrophage uptake rates. The microparticles are based on PEG graft copolymerized onto chitosan in combination with Pluronic(R) F-108 and were prepared via cryomilling. The synthesized polymers used in preparation of the microparticles were characterized using FTIR, EA, 2D-XRD, and differential scanning calorimetry (DSC). The microparticles size, morphology, moisture content, and biodegradation rates were investigated. Swelling studies and in vitro drug release profiles were determined. An aerosolization study was conducted and macrophage uptake rates were evaluated against controls. The microparticles showed a respirable fraction of approximately 15% when prepared as dry powders. Enzymatic degradation of microparticles started within the first hour and about 7-41% weights were remaining after 240 h. Microparticles showed sustained release up to 10 and 20 days in the presence and absence of lysozyme, respectively. Preliminary macrophage interaction studies indicate that the developed hydrogel microparticles significantly delayed phagocytosis and may have the potential for sustained drug delivery to the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.